Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic More: UCB reports positive outcomes for bimekizumab in psoriatic arthritis Source: News
read more
Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial More: AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension Source: News
read moreRoche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza for generic drugmakers to copy in 129 developing countries. More: Roche signs generic Xofluza licensing deal with Medicines Patent Pool for 129 countries Source: fierce
read moreTwo months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of those on Bimzelx achieved reduced
read moreWith questions already swirling about the actual affordability impact of the government’s drug purchasing portal TrumpRx, the White House is updating the platform to address a key gap in the medicines it lists, albeit with a number of caveats remaining.
read moreTakeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roughly tripled under antitrust law. More: Takeda
read more© 1994 - 2026 B.M. Pharmaceuticals